Staff Profile

Roles and Responsibilities

• Management of Newcastle Cancer Centre Pharmacology Group (NCCPG)
• Executive Board (Newcastle University Centre for Cancer)
• Lead on early phase clinical trials (PK/PD) in adult and childhood cancers
• Coordination of national paediatric clinical pharmacology studies
• Supervision of undergraduate, MRes and PhD student projects
• Teaching (BSc Pharmacology; MPharm Pharmacy; MRes Medical and Molecular Biosciences)

Areas of expertise

• Clinical pharmacology studies in oncology

Qualifications

• BSc Pharmacology (Hons), University of Liverpool
• Ph.D. (Clinical Pharmacology), University of Liverpool

Previous Positions

• 2010 to 2018 - Senior Lecturer, Northern Institute for Cancer Research, Newcastle University.
• 2005 to 2010 - Academic Fellow, Northern Institute for Cancer Research, Newcastle University.
• 2001 to 2005 - Senior Research Associate, Northern Institute for Cancer Research, Newcastle University.
• 1998 to 2001 - Postdoctoral Research Associate, Cancer Research Unit, Newcastle University.
• 1996 to 1998 - Postdoctoral Fellow, Division of Experimental Medicine and Haematology/Oncology, Harvard Medical School.

Memberships

Member of the following organisations :-

• Sarcoma UK Research Strategy Committee
• Great Ormond Street Charity External Grants Review Panel
• Children's Brain Tumour Drug Delivery Consortium (CBTDDC) Steering Group
• Children’s Cancer and Leukaemia Group (CCLG) (Pharmacology Subcommittee Chair)
• International Society of Paediatric Oncology (SIOP)
• Experimental Cancer Medicine Centres (ECMC) Paediatric Strategy Group
• EMA European Network of Paediatric Research (Enpr-EMA) Scientific Committee
• NCRI Children's Cancer and Leukaemia CSG Novel Agents Subgroup
• International Association of Therapeutic Drug Monitoring and Clinical Toxicology 
• British Pharmacological Society Clinical Committee
• British Association for Cancer Research (BACR)
• American Association for Cancer Research (AACR)
• European Association for Cancer Research (EACR) 

Honours and Awards

Awards/achievements :-

• Winner of the Children's Cancer and Leukaemia Group (CCLG) Innovation in Practice Award 2022 (April, 2022)
• Bright Ideas in Health Awards 2018 - Service Improvement Category Finalist (November, 2018)
• British Pharmacological Society (BPS) Clinical Oral Communication Award (December, 2016)
• Winner of the Quality in Care (QiC) Excellence in Oncology 'Best Innovation in Service Provision - Partnership Across the Pathway' Award for the establishment of a national therapeutic drug monitoring service for the treatment of children with cancer (December, 2013)
• BACR Mid-Career Fellowship (£2,000) – awarded to support a collaborative visit to the Tata Memorial Hospital, India (October, 2010)
• AACR-Merck Scholar-in-Training Award ($1,400) – received at the 100th Annual Meeting of the American Association of Cancer Research, Denver (April, 2009)
• AACR-GlaxoSmithKline Outstanding Clinical Scholar Award ($4,000) – received at the 95th Annual Meeting of the American Association of Cancer Research, Orlando (April, 2004)
• BACR Exchange Fellowship (£1,500) – received to support research carried out in laboratory of Dr. David Waxman, Boston University, USA (June – August, 2004)

Google Scholar: Click here.

SCOPUS: Click here.

Research Interests

I lead an enthusiastic and experienced research team based in the university Paul O'Gorman building (https://www.ncl.ac.uk/cancer/our-research/drug-discovery-and-pre-clinical-development/pharmacology/). Our research involves the design and coordination of clinical pharmacology studies involving both adults and children with cancer. These studies are associated with a wide range of approaches to cancer treatment including the development of novel agents, early phase clinical trials, the optimisation of established therapeutics and individualisation/personalisation of patient treatment. Studies are carried out at a national and European level involving the treatment of patients at centres throughout the UK and Europe. In addition to these clinical studies, I am involved in laboratory-based molecular and pharmacological translational research projects.

Other Expertise

Other research interests/expertise include the following :-

- biomarker studies

- therapeutic drug monitoring

- pharmacogenetic studies

- clinical welfare of children involved in research studies

Funding

Cancer Research UK

NIHR Research for Patient Benefit

NIHR Invention for Innovation (i4i)

UK Research and Innovation (Innovate UK)

Little Princess Trust

Bone Cancer Research Trust

European Commission Horizon 2020

Wellcome Trust Health Innovation Challenge Fund

Children with Cancer UK

European Commission Seventh Framework Programme (FP7)

Medical Research Council DPFS

Medical Research Council DTA

Research Councils UK

Sarcoma UK

Sparks Children's Medical Research Charity

Newcastle University Hospitals Special Trustees

Esteem Indicators

Editorial board member for European Journal of Cancer: Paediatric Oncology, Cancers, Pharmacology Research & Perspectives, Cancer Chemotherapy and Pharmacology and Frontiers in Oncology  

Reviewer for the following journals :-

- Journal of Clinical Oncology

- Clinical Cancer Research

- Molecular Cancer Therapeutics

- British Journal of Cancer

- European Journal of Cancer

- Cancer Chemotherapy and Pharmacology

- Clinical Pharmacokinetics

- Therapeutic Drug Monitoring

- Pediatric Blood and Cancer

- British Journal of Pharmacology

- Expert Opinion on Drug Delivery

- Pediatric Hematology and Oncology

- BMC Cancer

- Frontiers in Oncology

- Journal of Pediatric Hematology/Oncology

- British Journal of Clinical Oncology

- Journal of Pharmaceutical and Biomedical Analysis

- British Journal of Urology International

Undergraduate Teaching

BSc (Hons) Pharmacology

PED2001: Drug disposition and pharmacokinetics

PED3006: Carcinogenesis and anticancer drugs

Pharmacy MPharm Honours

PHAR2006: Pharmaceutical Care - pathology, patients and professionalism

Postgraduate Teaching

MRes in Medical and Molecular Biosciences (MMS8007: Cancer Studies)

MSc Medical Sciences (MMS8101: Research Practice in the 21st Century; MMS8107: Cancer Studies)

• Articles

  • Millen GC, Lawford A, Duncan C, Jenkinson H, Veal GJ, Barnett S. Utility of carboplatin therapeutic drug monitoring for the treatment of neonate and infant retinoblastoma patients in the United Kingdom. British Journal of Cancer 2024, 131, 491-497.
  • Serra R, Smith SJ, Rowlinson J, Gorelick N, Moloney C, McCrorie P, Veal GJ, Berry P, Chalmers AJ, Suk I, Shakesheff KM, Alexander C, Grundy RG, Brem H, Tyler BM, Rahman R. Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma. British Journal of Cancer 2024, epub ahead of print.
  • Bell HL, Blair HJ, Jepson Gosling SJ, Galler M, Astley D, Moorman AV, Heidenreich O, Veal GJ, van Delft FW, Lunec J, Irving JAE. Combination p53 activation and BCL-x_L/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia 2024, 38, 1223-1235.
  • Spiliopoulou P, Kazmi F, Aroldi F, Holmes T, Thompson D, Griffiths L, Qi C, Parkes M, Lord S, Veal GJ, Harrison DJ, Coyle VM, Graham J, Evans TRJ, Blagden SP. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental and Clinical Cancer Research 2024, 43(1), 100.
  • Spicer J, Basu B, Montes A, Banerji U, Kristeleit R, Miller R, Veal GJ, Corrigan CJ, Till SJ, Figini M, Canevari S, Barton C, Jones P, Mellor S, Carroll S, Selkirk C, Nintos G, Kwatra V, Funingana I-G, Doherty G, Gould HJ, Pellizzari G, Nakamura M, Ilieva KM, Khiabany A, Stavraka C, Chauhan J, Gillett C, Pinder S, Bax HJ, Josephs DH, Karagiannis SN. Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. Nature Communications 2023, 14(1), 4180.
  • Damoiseaux D, Amant F, Beijnen JH, Barnett S, Veal GJ, Huitema ADR, Dorlo TPC. Physiologically-based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk. CPT: Pharmacometrics and Systems Pharmacology 2023, 12(12), 1931-1944.
  • Barnett S, Makin G, Tweddle DA, Osborne C, Veal GJ. Generation of evidence-based carboplatin dosing guidelines for neonates and infants. British Journal of Cancer 2023, 129, 1773–1779.
  • Barnett S, Nyein AC, Galler M, Jamieson D, Davies M, Connor P, Veal GJ. Excessive vincristine exposure in a child being treated for acute lymphoblastic leukaemia with underlying Dubin–Johnson syndrome: a case report. Cancer Chemotherapy and Pharmacology 2023, 92, 325–328.
  • Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, Dragoni I, Heinzmann K, Potter S, Salisbury BM, Chenard-Poirier M, Greystoke A, Howell EC, Innes WA, Morris K, Plummer C, Rata M, Petrides G, Keun HC, Banerji U, Plummer R. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clinical Cancer Research 2023, 29(8), 1429-1439.
  • Lopez J, Lai-Kwon J, Molife R, Welsh L, Tunariu N, Roda D, Fernandez-Garcia P, Lladó V, McNicholl A, Roselló C, Taylor R, Azaro A, Ahnert JR, Sludden J, Veal G, Plummer R, Urruticoechea A, Lahuerta A, Mujika K, Escriba P. A Phase 1/2A trial of idroxioleic acid: First-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. British Journal of Cancer 2023, 129, 811-818.
  • Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN, Veal GJ, Klencke BJ, Kowalski MM, Banerji U. A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer 2023, 129, 38-45.
  • Barnett S, Hellman F, Parke E, Makin G, Tweddle DA, Osborne C, Hempel G, Veal GJ. Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients. European Journal of Cancer 2022, 164, 127-136.
  • Menne T, Slade D, Savage J, Johnson S, Irving J, Kearns P, Plummer R, Shenton G, Veal GJ, Vormoor B, Vormoor J, Billingham L. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. BMJ Open 2022, 12, e059872.
  • Apps JR, Maycock S, Ellison DW, Jaspan T, Ritzmann TA, Macarthur D, Malluci C, Wheatley K, Veal GJ, Grundy RG, Picton S. Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04). Neuro-Oncology Advances 2022, 4(1), 1-11.
  • Idowu OS, Craigen JL, Veal GJ, Jamieson D. Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum. Bioanalysis 2022, 14(18), 1241-1249.
  • Carruthers V, Barnett S, Rees R, Arif T, Slater O, Ramanujachar R, Johnson K, Brown S, Graham C, Burke GAA, Veal GJ. Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series. Pediatric Blood and Cancer 2022, 69(7), e29722.
  • Nijstad AL, Chu W-Y, de Vos-Kerkhof E, Enters-Weijnen CF, van de Velde ME, Kaspers GJL, Barnett S, Veal GJ, Lalmohamed A, Zwaan CM, Huitema ADR. A population pharmacokinetic modelling approach to unravel the complex pharmacokinetics of vincristine in children. Pharmaceutical Research 2022, 39, 2487-2495.
  • Veal GJ, Tweddle DA, Visser J, Errington J, Buck H, Marange J, Moss J, Joseph S, Mulla H. Pharmacokinetics and safety of a novel oral liquid formulation of 13-cis retinoic acid in children with neuroblastoma: A randomized crossover clinical trial. Cancers 2021, 13(8), 1868.
  • Barnett S, Errington J, Sludden J, Jamieson D, Poinsignon V, Paci A, Veal GJ. Pharmacokinetics and pharmacogenetics of cyclophosphamide in a neonate and infant childhood cancer patient population. Pharmaceuticals 2021, 14(3), 272.
  • Gowland C, Berry P, Errington J, Jeffrey P, Bennett G, Godfrey L, Pittman M, Niewiarowski A, Symeonides SN, Veal GJ. Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study. Bioanalysis 2021, 13(2), 101-113.
  • Gionfriddo I, Brunetti B, Mezzasoma F, Milano F, Cardinali V, Ranieri R, Venanzi A, Pierangeli S, Vetro C, Spinozzi G, Dorillo E, Wu H, Ciurnelli R, Griffin MJ, Jennings CE, Tiavvi E, Sportoletti E, Falzetti F, de The H, Veal GJ, Martelli MP, Falini B. Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated acute myeloid leukemia. Leukemia 2021, 35, 2552–2562.
  • Roberts E, Mogg JAW, Barnfield M, Veal GJ. Investigating current practices in renal function measurement and carboplatin dosing in children with cancer – a UK perspective. Pediatric Hematology and Oncology 2020, 37(3), 235-244.
  • Hawley J, Veal GJ, Errington J, McDonald LG, Tweddle DA. The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression. Pediatric Blood and Cancer 2019, 66(9), 1-3.
  • Chen L, Pastorino F, Berry P, Bonner J, Kirk C, Wood KM, Thomas HD, Zhao Y, Daga A, Veal GJ, Lunec J, Newell DR, Ponzoni M, Tweddle DA. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. International Journal of Cancer 2019, 144(12), 3146-3159.
  • Duong JK, Veal GJ, Nath CE, Shaw PJ, Errington J, Ladenstein R, Boddy AV. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: A re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function. British Journal of Clinical Pharmacology 2019, 85(1), 136-146.
  • Lee CM, Zane NR, Veal G, Thakker DR. Physiologically Based Pharmacokinetic Models for Adults and Children Reveal a Role of Intracellular Tubulin Binding in Vincristine Disposition. CPT Pharmacometrics and Systems Pharmacology 2019, 8(10), 759-768.
  • Smith SJ, Tyler BM, Gould T, Veal GJ, Gorelick N, Rowlinson J, Serra R, Ritchie A, Berry P, Otto A, Choi J, Skuli N, Estevez-Cebrero M, Shakesheff KM, Brem H, Grundy RG, Rahman R. Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. Clinical Cancer Research 2019, 25(16), 5094-5106.
  • Jackson RK, Liebich M, Berry P, Errington J, Liu J, Parker C, Moppett J, Samarasinghe S, Hough R, Rowntree C, Goulden NJ, Vora A, Kearns PR, Saha V, Hempel G, Irving JAE, Veal GJ. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia - a report from the UKALL 2011 trial. European Journal of Cancer 2019, 120, 75-85.
  • Matheson EC, Thomas H, Case M, Blair H, Jackson RK, Masic D, Veal G, Halsey C, Newell DR, Vormoor J, Irving JAE. Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM. Haematologica 2019, 104(9), 1804-1811.
  • Adamson PC, Veal GJ, Womer RB, Meany HJ, Bernhardt MB, Frazier AL, Balis FM. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function. Pediatric Blood and Cancer 2019, 66(6), e27672.
  • Danilenko M, Hodgson K, Stones R, Husain A, Zangarini M, Veal G, Rajan N. Diverse assays from a single skin punch biopsy to assess topical drug intervention. British Journal of Dermatology 2019, 180(4), 937-938.
  • Uitrakul S, Hutton C, Veal GJ, Jamieson D. A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells. European Journal of Clinical Investigation 2019, 49(7), e13115.
  • Yogev O, Almeida GS, Barker KT, George SL, Kwok C, Campbell J, Zarowiecki M, Kleftogiannis D, Smith LM, Hallsworth A, Berry P, Möcklinghoff T, Webber HT, Danielson LS, Buttery B, Calton EA, da Costa BM, Poon E, Jamin Y, Lise S, Veal GJ, Sebire N, Robinson SP, Anderson J, Chesler L. In vivo Modelling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. Cancer Research 2019, 79(20), 5382-5393.
  • Thomas F, Veal GJ, El Balkhi S, Lafont T, Picard N, Brugieres L, Chatelut E, Piguet C. Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemotherapy and Pharmacology 2018, 82(2), 361-365.
  • Kim HY, Veal GJ, Zhou F, Boddy AV. The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients. European Journal of Clinical Pharmacology 2018, 74(12), 1575-1584.
  • Martinez-Soria N, McKenzie L, Draper J, Ptasinska A, Issa H, Potluri S, Blair HJ, Pickin A, Isa A, Chin PS, Tirtakusuma R, Coleman D, Nakjang S, Assi S, Forster V, Reza M, Law E, Berry P, Mueller D, Elder A, Bomken SN, Pal D, Allan JM, Veal GJ, Cockerill PN, Wichmann C, Vormoor J, Lacaud G, Bonifer C, Heidenreich O. The Oncogenic Transcription Factor RUNX1/ETO Corrupts Cell Cycle Regulation to Drive Leukemic Transformation. Cancer Cell 2018, 34(4), 626-642.e8.
  • Fischer-Huchzermeyer S, Chikobava L, Stahn V, Zangarini M, Berry P, Veal GJ, Senner V, Mautner VF, Harder A. Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. BMC Research Notes 2018, 11(1), 520.
  • Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N. Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib. JAMA Dermatology 2018, 154(8), 913-921.
  • Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. New England Journal of Medicine 2018, 378(25), 2376-2385.
  • White-Koning M, Osborne C, Paci A, Boddy AV, Chatelut E, Veal GJ. Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. European Journal of Cancer 2018, 91, 56-67.
  • Veal GJ, Malik S, Lupo M, MacFarlane S, Lepola P, Costello M, Ceci A, Boué C, Lecour L, Otto A, Rastegari M, Berry P. Investigating the roles and training of paediatric research nurses working across Europe: a questionnaire-based survey. BMJ Paediatrics Open 2017, 1(1), 1-7.
  • Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marple M, Veal G, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi H, Beare S. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncology 2017, 18(10), 1397-1410.
  • Zangarini M, Rajan N, Danilenko M, Berry P, Traversa S, Veal GJ. Development and validation of LC–MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors. Bioanalysis 2017, 9(3), 279-288.
  • Zangarini M, Berry P, Sludden J, Raynaud FI, Banerji U, Jones P, Edwards D, Veal GJ. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. Bioanalysis 2017, 9(13), 1001-1010.
  • Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J. A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. Pediatric Blood & Cancer 2017, 64(6), e26351 1-4.
  • Gota V, Chinnaswamy G, Vora T, Rath S, Yadav A, Gurjar M, Veal G, Kurkure P. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. Cancer Chemotherapy and Pharmacology 2016, 78(4), 763-768.
  • Siebert N, Eger C, Seidel D, Jüttner M, Zumpe M, Wegner D, Kietz S, Ehlert K, Veal GJ, Siegmund W, Weiss M, Loibner H, Ladenstein R, Lode HN. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long term infusion in combination with IL-2. mAbs 2016, 8(3), 604-616.
  • Jackson RK, Irving JAE, Veal GJ. Personalisation of dexamethasone therapy in childhood acute lymphoblastic leukaemia. British Journal of Haematology 2016, 173(1), 13-24.
  • Errington J, Malik G, Evans J, Baston J, Parry A, Price L, Johnstone H, Peters S, Oram V, Howe K, Whiteley E, Tunnacliffe J, Veal GJ. Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK. Pediatric Blood & Cancer 2016, 63(7), 1193-1197.
  • Walsh C, Bonner JJ, Johnson TN, Neuhoff S, Ghazaly EA, Gribben JG, Boddy AV, Veal GJ. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. British Journal of Clinical Pharmacology 2016, 81(5), 989-998.
  • Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV. Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. European Journal of Cancer 2016, 55, 56–64.
  • Veal GJ, Errington J, Sastry J, Chisholm J, Brock P, Morgenstern D, Pritchard-Jones K, Chowdhury T. Adaptive dosing of anticancer drugs in neonates – facilitating evidence-based dosing regimens. Cancer Chemotherapy and Pharmacology 2016, 77(4), 685-692.
  • Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RM, Tweddle DA, Jenkinson H, Picton S. Carboplatin therapeutic monitoring in preterm and full-term neonates. European Journal of Cancer 2015, 51(14), 2022-2030.
  • Avan A, Adema AD, Hoebe EK, Huijts CM, Avan A, Veal GJ, Ruijtenbeek R, Wosikowski K, Peters GJ. Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib. Current Drug Targets 2014, 15(14), 1312-1321.
  • Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ. Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer. Clinical Pharmacokinetics 2014, 53(8), 741-751.
  • Hill CR, Jamieson D, Thomas HD, Brown CDA, Boddy AV, Veal GJ. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo. Biochemical Pharmacology 2013, 85(1), 29-37.
  • Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson ADJ, Boddy AV. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clinical Cancer Research 2013, 19(2), 469-479.
  • Jarvis IWH, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ. Therapy induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tumours. Biochemical Pharmacology 2012, 83(1), 69-77.
  • Armstrong JL, Martin S, Illingworth NA, Jamieson D, Neilson A, Lovat PE, Redfern CPF, Veal GJ. The impact of retinoic acid treatment on the sensitivity of neuroblastoma cells to fenretinide. Oncology Reports 2012, 27(1), 293-298.
  • Gomaa MS, Lim AST, Wilson-Lau SC, Watts AM, Illingworth NA, Bridgens CE, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C. Synthesis and CYP26A1 inhibitory activity of novel methyl 3-[4-(arylamino)phenyl]-3-(azole)-2,2-dimethylpropanoates. Bioorganic & Medicinal Chemistry 2012, 20(20), 6080-6088.
  • Daly AK, Veal GJ, Jamieson D, Coulthard S. Pharmacogenomics research at Newcastle University. Pharmacogenomics 2012, 13(12), 1333-1338.
  • Gomaa MS, Bridgens CE, Illingworth NA, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold. Bioorganic & Medicinal Chemistry 2012, 20(14), 4201-4207.
  • Orienti I, Zuccari G, Falconi M, Teti G, Illingworth NA, Veal GJ. Novel micelles based on amphiphilic branched PEG as carriers for fenretinide. Nanomedicine: Nanotechnology, Biology and Medicine 2012, 8(6), 880-890.
  • Veal GJ, Boddy AV. Chemotherapy in newborns and preterm babies. Seminars in Fetal and Neonatal Medicine 2012, 17(4), 243-248.
  • Veal GJ, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D, Brock P, Ladenstein R, Vassal G. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. European Journal of Cancer 2012, 48(16), 3063-3072.
  • Gomaa MS, Bridgens CE, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C. Synthesis and Biological Evaluation of 3-(1H-Imidazol- and Triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl Derivatives as Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26). Journal of Medicinal Chemistry 2011, 54(19), 6803-6811.
  • Gomaa MS, Bridgens CE, Aboraia AS, Veal GJ, Redfern CPF, Brancale A, Armstrong JL, Simons C. Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(aryl-2-ylamino)phenyl)propanoates. Journal of Medicinal Chemistry 2011, 54(8), 2778-2791.
  • Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M. Pharmacokinetics of cyclophosphamide and its metabolites in pediatric patients receiving high-dose myeloablative therapy. European Journal of Cancer 2011, 47(10), 1556-1563.
  • Illingworth NA, Boddy AV, Daly AK, Veal GJ. Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. British Journal of Pharmacology 2011, 162(4), 989-999.
  • Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV. Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug Metabolism and Disposition 2010, 38(7), 1211-1217.
  • Rowbotham SE, Boddy AV, Redfern CPF, Veal GJ, Daly AK. Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metabolism and Disposition 2010, 38(8), 1261-1266.
  • Armstrong JL, Flockhart R, Veal GJ, Lovat PE, Redfern CPF. Regulation of Endoplasmic Reticulum Stress-induced Cell Death by ATF4 in Neuroectodermal Tumor Cells. Journal of Biological Chemistry 2010, 285(9), 6091-6100.
  • Veal GJ, Cole M, Errington J, Pearson ADJ, Gerrard M, Whyman G, Ellershaw C, Boddy AV. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients. Cancer Chemotherapy and Pharmacology 2010, 65(6), 1057-1066.
  • Giraud B, Hebert G, Deroussent A, Veal GJ, Vassal G, Paci A. Oxazaphosphorines: New therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism and Toxicology 2010, 6(8), 919-938.
  • Israels T, Damen CWN, Cole M, van Geloven N, Boddy AV, Caron HN, Beijnen JH, Molyneux EM, Veal GJ. Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate. European Journal of Cancer 2010, 46(10), 1841-1847.
  • Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. Journal of Clinical Oncology 2010, 28(32), 4790-4799.
  • Nannizi S, Veal GJ, Giovannetti E, Mey V, Ricciardi S, Ottley CJ, Del Tacca M, Danesi R. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines. Cancer Chemotherapy and Pharmacology 2010, 66(3), 547-558.
  • Picton S, Keeble J, Holden V, Errington J, Boddy AV, Veal GJ. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemotherapy and Pharmacology 2009, 63(4), 749-752.
  • Rhodin M, Anderson B, Peters A, Coulthard M, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir M, Holford N. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatric Nephrology 2009, 24, 67-76.
  • Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, Boddy AV, Adamson PC, Barrett JS. Population pharmacokinetic investigation of actinomycin D in children and young adults. Journal of Clinical Pharmacology 2008, 48(1), 35-42.
  • Gomaa MS, Armstrong JL, Bobillon B, Veal GJ, Brancale A, Redfern CPF, Simons C. Novel azolyl-(phenylmethyl)]aryl/heteroarylamines: Potent CYP26 inhibitors and enhancers of all-trans retinoic acid activity in neuroblastoma cells. Bioorganic and Medicinal Chemistry 2008, 16(17), 8301-8313.
  • Chinnaswamy G, Cole M, Boddy AV, Keir M, Price L, Parry AP, English M, Veal GJ. Estimation of renal function and its potential impact on carboplatin dosing in children with cancer. British Journal of Cancer 2008, 99(6), 894-899.
  • Armstrong, J.L., Veal, G.J., Redfern, C.P.F., Lovat, P.E. Role of Noxa in p53-independent fenretinide-induced apoptosis of neuroectodermal tumours. Apoptosis 2007, 12(3), 613-622.
  • Veal, G. J., Rowbotham, S., Boddy, A. V. Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma. Therapie 2007, 62(2), 91-93.
  • Veal GJ, Cole M, Errington J, Pearson ADJ, Foot A, Whyman G, Boddy AV. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group. British Journal of Cancer 2007, 96(3), 424-431.
  • Armstrong J, Taylor GA, Thomas HD, Boddy AV, Redfern C, Veal GJ. Molecular targeting of retinoic acid metabolism in neuroblastoma: The role of the CYP26 inhibitor R116010 in vitro and in vivo. British Journal of Cancer 2007, 96(11), 1675-1683.
  • Veal GJ, Errington J, Tilby MJ, Pearson ADJ, Foot A, McDowell H, Ellershaw C, Pizer B, Nowell G, Pearson D, Boddy AV. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours. British Journal of Cancer 2007, 96(5), 725-731.
  • Cole M, Price L, Parry AP, Picton S, Waters F, Marshall S, Goran C, Parnham A, Wastell H, Reid M, Pearson ADJ, Boddy AV, Veal GJ. A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer. Pediatric Blood and Cancer 2007, 48(7), 687-695.
  • Cole M, Boddy AV, Kearns P, Teh KH, Price L, Parry A, Pearson ADJ, Veal GJ. Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?. Pediatric Blood and Cancer 2006, 46(7), 723-727.
  • Jounaidi Y, Chen C-S, Veal GJ, Waxman DJ. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low K_m cyclophosphamide 4-hydroxylase P450 2B11. Molecular Cancer Therapeutics 2006, 5(3), 541-555.
  • Veal GJ, Errington J, Thomas HD, Boddy AV, Lowis S. Biliary excretion of etoposide in children with cancer. Cancer Chemotherapy and Pharmacology 2006, 58(3), 415-417.
  • Veal, G. J., Cole, M., Errington, J., Parry, A. P., Hale, J. P., Pearson, A. D. J., Howe, K., Chisholm, J., Beane, C., Brennan, B., Waters, F., Glaser, A., Hemsworth, S., McDowell, H., Wright, Y., Pritchard-Jones, K., Pinkerton, R., Jenner, G., Nicholson, J., Elsworth, A., Boddy, A. V. Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group study. Clinical Cancer Research 2005, 11(16), 5893-5899.
  • Armstrong, J., Ruiz, M., Boddy, A. V., Redfern, C., Pearson, A. D. J., Veal, G. J. Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. British Journal of Cancer 2005, 92(4), 696-704.
  • Veal, G. J., English, M., Grundy, R., Shakespeare, C., Glaser, A., Waters, F., Holden, V., O'Meara, A., Michalski, A., Howe, K., Cole, S., Boddy, A. V. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy. Cancer Chemotherapy and Pharmacology 2004, 54(4), 295-300.
  • Cole M, Price L, Parry AP, Keir M, Pearson ADJ, Boddy A V, Veal GJ. Estimation of glomerular filtration rate in paediatric cancer patients using ⁵¹CR-EDTA population pharmacokinetics. British Journal of Cancer 2004, 90(1), 60-64.
  • Cooper, B., Veal, G.J., Radivoyevitch, T., Tilby, M., Meyerson, H., Lazarus, H., Koc, O., Creger, R., Pearson, G., Nowell, G., Gosky, D., Ingalls, S., Hoppel, C., Gerson, S. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia. Clinical Cancer Research 2004, 10(20), 6830-6839.
  • Veal, G. J., Errington, J., Sludden, J., Griffin, M. J., Price, L., Parry, A. P., Hale, J. P., Pearson, A. D. J., Boddy, A. V. Determination of anti-cancer drug actinomycin D in human plasma by liquid chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2003, 795(2), 237-243.
  • Rana B, Veal GJ, Pearson ADJ, Redfern CPF. Retinoid X receptors and retinoid response in neuroblastoma cells. Journal of Cellular Biochemistry 2002, 86(1), 67-78.
  • Veal, G. J., Errington, J., Redfern, C., Pearson, A. D. J., Boddy, A. V. Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochemical Pharmacology 2002, 63(2), 207-215.
  • Veal, G. J., Errington, J., Redfern, C. P. F., Pearson, A. D. J., Boddy, A. V. Influence of retinoid isomerisation on the cellular activity of 13-cis retinoic acid in neuroblastoma. British Journal of Cancer 2001, 85(1), 93-97.
  • Veal, G. J., Dias, C., Price, L., Parry, A. P., Errington, J., Hale, J. P., Pearson, A. D. J., Boddy, A. V., Newell, D. R., Tilby, M. J. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clinical Cancer Research 2001, 7(8), 2205-2212.
  • Veal, G. J., Griffin, M., Price, E., Parry, A. P., Dick, G., Little, M., Yule, S., Morland, B., Estlin, E., Hale, J. P., Pearson, A. D. J., Welbank, H., Boddy, A. V. A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin. British Journal of Cancer 2001, 84(8), 1029-1035.

• Letters

  • Geurten C, Errington J, Barnett S, Patel H, Noor S, Saraff V, Veal GJ, Gatz SA. Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma. Pediatric Blood and Cancer 2023, 70(9), e30430.
  • Veal GJ, Boddy AV. Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring. Journal of Clinical Oncology 2012, 30(27), 3424.

• Reviews

  • Meijer AJM, Diepstraten FA, Ansari M, Bouffet E, Bleyer A, Fresneau B, Geller JI, Huitema ADR, Kogner P, Maibach R, O'Neill AF, Papadakis V, Rajput KM, Veal GJ, Sullivan M, van den Heuvel-Eibrink MM, Brock PR. The use of sodium thiosulfate as an otoprotectant in cancer patients treated with platinum compounds: a review of the literature. Journal of Clinical Oncology 2024, 42(18), 2219-2232.
  • Berezowska M, Hayden IS, Brandon AM, Zats A, Patel M, Barnett S, Ogungbenro K, Veal GJ, Taylor A, Suthar J. Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. British Journal of Clinical Pharmacology 2024, epub ahead of print.
  • Rahman R, Janowski M, Killick-Cole CL, Singleton WGB, Campbell E, Walczak P, Khatua S, Faltings L, Symons M, Schneider JR, Kwan K, Boockvar JA, Gill SS, Oliveira JM, Beccaria K, Carpentier A, Canney M, Pearl M, Veal GJ, Meijer L, Walker DA. Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials. Cancers 2023, 15(3), 857.
  • Barnett S, Holden V, Campbell-Hewson Q, Veal GJ. Perspectives and expertise in establishing a therapeutic drug monitoring programme for challenging childhood cancer patient populations. Frontiers in Oncology 2022, 11, 815040.
  • Nijstad AL, Barnett S, Lalmohamed A, Bérénos IM, Parke E, Carruthers V, Tweddle DA, Kong J, Zwaan CM, Huitema ADR, Veal GJ. Clinical pharmacology of cytotoxic drugs in neonates and infants: providing evidence-based dosing guidance. European Journal of Cancer 2022, 164, 137-154.
  • Barnett S, Kong J, Makin G, Veal GJ. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. British Journal of Clinical Pharmacology 2021, 87(2), 256-262.
  • Veal GJ, Amankwatia EB, Paludetto M-N, Möcklinghoff T, Thomson F, André N, Ciccolini J, Chatelut E. Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. Therapeutic Drug Monitoring 2019, 41(2), 142-159.
  • Bardin C, Veal G, Paci A, Chatelut E, Astier A, Leveque D, Widmer N, Beijnen J. Therapeutic drug monitoring in cancer – Are we missing a trick?. European Journal of Cancer 2014, 50(12), 2005-2009.
  • Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Leveque D, Veal G, Astier A. Review of therapeutic drug monitoring of anticancer drugs part 2 – Targeted therapies. European Journal of Cancer 2014, 50(12), 2020-2036.
  • Paci A, Veal G, Bardin C, Leveque D, Widmer N, Beijnen J, Astier A, Chatelut E. Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics. European Journal of Cancer 2014, 50(12), 2010-2019.
  • Veal GJ. Blood volumes in paediatric clinical trials: a review of current regulations and guidance for research studies. Clinical Investigation 2014, 4(11), 1005-1011.
  • Armstrong, J.L., Redfern, C.P.F., Veal, G.J. 13-cis Retinoic acid and isomerisation in paediatric oncology - Is changing shape the key to success?. Biochemical Pharmacology 2005, 69(9), 1299-1306.
  • Estlin E, Veal G. Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treatment Reviews 2003, 29(4), 253-273.
  • Veal, G. J., Coulthard, S., Boddy, A. V. Chemotherapy individualization. Investigational New Drugs 2003, 21(2), 149-156.